CN107427698A - 肺高血压的组合疗法 - Google Patents

肺高血压的组合疗法 Download PDF

Info

Publication number
CN107427698A
CN107427698A CN201680015289.1A CN201680015289A CN107427698A CN 107427698 A CN107427698 A CN 107427698A CN 201680015289 A CN201680015289 A CN 201680015289A CN 107427698 A CN107427698 A CN 107427698A
Authority
CN
China
Prior art keywords
pulmonary
bmpr2
patient
pah
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680015289.1A
Other languages
English (en)
Chinese (zh)
Inventor
L.古
P.C.纳卡加基
N.S.巴奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivus LLC
Original Assignee
Vivus LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus LLC filed Critical Vivus LLC
Publication of CN107427698A publication Critical patent/CN107427698A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680015289.1A 2015-01-13 2016-01-08 肺高血压的组合疗法 Pending CN107427698A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103020P 2015-01-13 2015-01-13
US62/103020 2015-01-13
PCT/US2016/012694 WO2016114993A1 (en) 2015-01-13 2016-01-08 Combination therapy for pulmonary hypertension

Publications (1)

Publication Number Publication Date
CN107427698A true CN107427698A (zh) 2017-12-01

Family

ID=56406244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015289.1A Pending CN107427698A (zh) 2015-01-13 2016-01-08 肺高血压的组合疗法

Country Status (12)

Country Link
US (4) US20180325875A1 (enExample)
EP (1) EP3244968B1 (enExample)
JP (1) JP6890540B2 (enExample)
KR (1) KR102569428B1 (enExample)
CN (1) CN107427698A (enExample)
AU (1) AU2016207046B2 (enExample)
BR (1) BR112017014914B1 (enExample)
CA (1) CA2973114C (enExample)
IL (1) IL253325A0 (enExample)
MX (1) MX2017009110A (enExample)
NZ (1) NZ733451A (enExample)
WO (1) WO2016114993A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP2019533713A (ja) * 2016-11-10 2019-11-21 アレーナ ファーマシューティカルズ，インク． ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
CN110381951A (zh) * 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物
BR112022010311A2 (pt) 2019-11-29 2022-08-16 Actelion Pharmaceuticals Ltd Métodos de tratamento de hipertensão arterial pulmonar

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171193A1 (en) * 2008-06-12 2011-07-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
US20130251787A1 (en) * 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of Pulmonary Hypertension with Leukotriene Inhibitors
US20140135358A1 (en) * 2011-05-02 2014-05-15 Edda Spiekerkoetter Use of FK506 for the Treatment of Pulmonary Arterial Hypertension

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814131A (zh) 2011-05-09 2014-05-21 格拉斯哥大学理事会 在肺动脉高血压的治疗中调控microrna的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171193A1 (en) * 2008-06-12 2011-07-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
US20140135358A1 (en) * 2011-05-02 2014-05-15 Edda Spiekerkoetter Use of FK506 for the Treatment of Pulmonary Arterial Hypertension
US20130251787A1 (en) * 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of Pulmonary Hypertension with Leukotriene Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵丽: "FDA批准利奥西呱治疗慢性栓塞性肺动脉高压", 《国际药学研究杂志》 *

Also Published As

Publication number Publication date
RU2017128481A3 (enExample) 2019-06-25
EP3244968B1 (en) 2023-08-30
KR20170103918A (ko) 2017-09-13
EP3244968A1 (en) 2017-11-22
BR112017014914B1 (pt) 2023-11-14
EP3244968A4 (en) 2018-09-12
CA2973114C (en) 2023-04-04
KR102569428B1 (ko) 2023-08-21
AU2016207046B2 (en) 2021-04-01
CA2973114A1 (en) 2016-07-21
US20200069658A1 (en) 2020-03-05
NZ733451A (en) 2023-02-24
US20210267951A1 (en) 2021-09-02
US20240238259A1 (en) 2024-07-18
WO2016114993A1 (en) 2016-07-21
BR112017014914A2 (pt) 2018-03-13
JP6890540B2 (ja) 2021-06-18
US20180325875A1 (en) 2018-11-15
JP2018502126A (ja) 2018-01-25
RU2017128481A (ru) 2019-02-14
AU2016207046A1 (en) 2017-07-27
MX2017009110A (es) 2017-11-09
IL253325A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US20240238259A1 (en) Combination therapy for pulmonary hypertension
CA2669536C (en) Combinations of ambrisentan and pde5 inhibitors for treating pulmonary arterial hypertension
CN103458690B (zh) 治疗肺动脉高压的组合物和方法
US20130225595A1 (en) Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
BG106946A (bg) Използване на антагонисти на централни канабиноидни рецептори за получаване на лекарствени средстваза улесняване спирането на консумацията на тютюн
US20210338642A1 (en) Compositions and methods for the treatment or prevention of pulmonary hypertension
KR20230038234A (ko) 만성 신장 질환 치료를 위한 지보텐탄 및 다파글리플로진의 조합
WO2010062640A1 (en) Methods for treating idiopathic pulmonary fibrosis and associated complications
RU2780758C2 (ru) Комбинированная терапия легочной гипертензии
EP4376843A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
WO2005077418A1 (en) Combination of renin inhibitor and diuretics
US20080312250A1 (en) Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
US20070072848A1 (en) Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
JP2011213713A (ja) アンジオテンシンｉｉ受容体拮抗剤の配合剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171201